Olfactory disorders in coronavirus disease 2019 patients: a systematic literature review

Fuccillo, Emanuela; Saibene, Alberto Maria; Canevini, Maria Paola; Felisati, Giovanni

doi:10.1017/s0022215120002005

Cited by 18 publications

(27 citation statements)

References 63 publications

(92 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…13,31 Such a wide range may be explained with the heterogeneity of the study protocols. 36 Our results are consistent with those of other studies conducted with hospitalised patients. 19,37 On the contrary, some studies have reported lower or higher olfactory dysfunction or taste impairment.…”

Section: Discussionsupporting

confidence: 93%

Olfactory dysfunction and coronavirus disease 2019 severity: a prospective cohort study

et al. 2021

View full text Add to dashboard Cite

Objective. The primary goal of this study was to evaluate the association between olfactory dysfunction or taste impairment olfactory dysfunction and disease severity and radiological findings in coronavirus disease-2019. The secondary goal was to assess the prevalence, severity and course of olfactory dysfunction or taste impairment in patients with coronavirus disease 2019.Method. This prospective observational cohort study evaluated patients hospitalised with coronavirus disease 2019 between April 1 and 1 May 2020. olfactory dysfunction and taste impairment were evaluated by two questionnaires. Chest computed tomography findings and coronavirus disease 2019 severity were assessed.Results. Among 133 patients, 23.3 per cent and 30.8 per cent experienced olfactory dysfunction and taste impairment, respectively, and 17.2 per cent experienced both. The mean age was 56.03 years, and 64.7 per cent were male and 35.3 per cent were female. No statistically significant association was found between https://www.cambridge.org/core/terms.

show abstract

Section: Discussionsupporting

confidence: 93%

Olfactory dysfunction and coronavirus disease 2019 severity: a prospective cohort study

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Despite the overall improving trend, only 40% of patients recovered completely from the OGD at T3. Resolution rate appear to be variable in literature, ranging from 13% [39] to 86% [40] , mainly depending on follow-up duration and OGD evaluation methodology (quantitative vs qualitative) [41] , [42] . In our sample, severity at onset was the most relevant variable influencing complete resolution.…”

Section: Discussionmentioning

confidence: 99%

Clinical, virological and immunological evolution of the olfactory and gustatory dysfunction in COVID-19

Maiorano

Calastri

Robotti

et al. 2022

American Journal of Otolaryngology

View full text Add to dashboard Cite

Purpose New-onset olfactory and gustatory dysfunction (OGD) represents a well-acknowledged COVID-19 red flag. Nevertheless, its clinical, virological and serological features are still a matter of debate. Materials and methods For this cohort study, 170 consecutive subjects with new-onset OGD were consecutively recruited. Otolaryngological examination, OGD subjective grading, nasopharyngeal swabs (NS) for SARS-CoV-2 RNA detection and serum samples (SS) collection for SARS-CoV-2 IgG quantification were conducted at baseline and after one (T1), two (T2) and four weeks (T3). Results SARS-CoV-2 infection was confirmed in 79% of patients. Specifically, 43% of positive patients were detected only by SS analysis. The OGD was the only clinical complaint in 10% of cases. Concurrent sinonasal symptoms were reported by 45% of patients. Subjective improvement at T3 was reported by 97% of patients, with 40% recovering completely. Hormonal disorders and RNA detectability in NS were the only variables associated with OGD severity. Recovery rate was higher in case of seasonal influenza vaccination, lower in patients with systemic involvement and severe OGD. Not RNA levels or IgG titers were correlated with recovery. Conclusion Clinical, virological and serological features of COVID-19 related OGD were monitored longitudinally, offering valuable hints for future research on the relationship between host characteristics and chemosensory dysfunctions.

show abstract

“…Smell and taste impairment is a well-known sequelae of upper respiratory tract infections. 6 The reported incidence of olfactory dysfunction following upper respiratory tract infection is between 20% and 40%. 1 For typical upper respiratory tract infections, the associated smell and taste impairment mostly occurs as a result of nasal obstruction, which differs from the impairment in patients with COVID-19.…”

Section: Discussionmentioning

confidence: 99%

Taste and Smell Impairment in Critically Ill Patients With COVID-19: An Intensive Care Unit Study

et al. 2020

View full text Add to dashboard Cite

Objective: To determine taste and smell impairment rates in patients with coronavirus disease 2019 (COVID-19) who were hospitalized in the intensive care unit (ICU). Methods: Between March 2020 and May 2020, patients with COVID-19 hospitalized in the ICU were enrolled in this study. Upon discharge, patients were telephoned and asked to complete a survey related to taste and smell impairment. Characteristics were compared between patients with and without taste and/or smell impairment. Results: Fifty-two patients were enrolled (mean age, 61.32 ± 12.53 years; mean ICU stay, 10.19 ± 10.24 days). Age, sex, type/number of comorbid diseases, most ICU support modalities, and ICU stay duration did not significantly differ between groups. Patients in group B required more high-flow nasal oxygen therapy than patients in group A ( P = .010). In total, 22 (42.3%) of 52 patients experienced taste and/or smell impairment. Three patients experienced isolated smell impairment and one patient experienced isolated taste impairment. Among the 21 patients who experienced smell impairment, 18 (85.78%) experienced hyposmia (mean visual analog scale [VAS] score: 6.33 ± 0.97), while 3 (14.28%) experienced anosmia. Among the 19 patients who experienced taste impairment, 16 (84.22%) experienced hypogeusia (mean VAS score: 6.43 ± 1.03) and 3 (15.78%) experienced ageuisa. Among 22 patients who experienced taste and/or smell impairment, 15 (68.18%) patients (n = 15/22) experienced smell and/or taste impairment before the ICU stay, while 7 (31.82%) patients (n = 7/22) experienced impairment during the ICU stay. Overall, 28.84% (n = 15/52) of the patients experienced taste and/or smell impairment before the ICU stay. Conclusions: Patients who were hospitalized in the ICU experienced lower rates of taste and/or smell impairment. Some patients experienced taste and/or smell impairment during the ICU stay.

show abstract

Olfactory disorders in coronavirus disease 2019 patients: a systematic literature review

Cited by 18 publications

References 63 publications

Olfactory dysfunction and coronavirus disease 2019 severity: a prospective cohort study

Olfactory dysfunction and coronavirus disease 2019 severity: a prospective cohort study

Clinical, virological and immunological evolution of the olfactory and gustatory dysfunction in COVID-19

Taste and Smell Impairment in Critically Ill Patients With COVID-19: An Intensive Care Unit Study

Contact Info

Product

Resources

About